HUTCHMED (China) Limited

Equities

HCM

KYG4672N1198

Pharmaceuticals

Market Closed - London S.E. 12:35:28 2024-03-28 pm EDT 5-day change 1st Jan Change
267.5 GBX +1.13% Intraday chart for HUTCHMED (China) Limited -2.90% -5.48%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Sector Update: Health Care Stocks Advance Premarket Thursday MT
Hutchmed lung cancer treatment accepted for review in China AN
Hutchmed Says Supplemental New Drug Application for Savolitinib Accepted for Review in China MT
JD Sports backs outlook; Spirent accepts new offer AN
Hutchmed (China)'s NDA Application Accepted by Chinese Authorities MT
HUTCHMED Limited Announces Savolitinib sNDA Accepted in China for Treatment-Naive or Previously Treated Patients with Locally Advanced or Metastatic MET Exon 14 NSCLC CI
Hutchmed begins registration stage for sovleplenib phase 2/3 trial AN
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug MT
Hutchmed (China) Initiates Phase II/III Clinical Trials for Autoimmune Disease Drug MT
Hutchmed Initiates Registration Stage of the Eslim-02 Phase Ii/Iii Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in China CI
Hutchmed Returns to Profit in 2023; EPS Tops Estimate MT
EARNINGS: Hutchmed revenue surges, Craven House's loss widens AN
Hutchmed Swings to 2023 Profit as Revenue Increases MT
Hutchmed (China) Swings to Profit in FY23; Revenue Soars MT
Transcript : HUTCHMED Limited, 2023 Earnings Call, Feb 28, 2024
HUTCHMED Limited Provides Revenue Guidance for the Year 2024 CI
HUTCHMED Limited Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Hutchmed hails fruquintinib trial results for gastric cancer treatment AN
Hutchmed Presents Phase 3 Trial Results for Gastric Cancer Drug at US Oncology Meet; Shares Rise 4% MT
An undisclosed buyer acquired 50% stake in Hutchison Hain Organic Holdings Limited from HUTCHMED Limited. CI
Hutchmed Limited Highlights Presentation of Phase III Data on Fruquintinib in Second-Line Gastric Cancer At Asco Plenary Series Session CI
Hutchmed Says Inmagene Exercises Option to License Two Drug Candidates MT
Hutchmed says Inmagene exercises option to licence drug candidates AN
Hutchmed Secures Marketing Approval for Cancer Therapy in Hong Kong MT
Hurchmed Receives Hong Kong Approval to Market Elunate MT
Chart HUTCHMED (China) Limited
More charts
HUTCHMED China Ltd, formerly Hutchison China Meditech Ltd, is an investment holding company principally engaged in the manufacturing and sale of drugs. Along with subsidiaries, the Company operates its business through two segments. The Oncology and Immunology segment is engaged in discovering, developing, and commercializing targeted therapies and immunotherapies for the treatment of cancer and immunological diseases, including research and development activities covering drug discovery, development, manufacturing and regulatory functions as well as administrative activities to support research and development operations, also covering sales, marketing, manufacturing and distribution of drug developed from research and development activities. The Other Ventures segment is involved in other commercial businesses including the sales, marketing, manufacturing and distribution of other prescription drugs and over-the-counter pharmaceuticals as well as consumer health products.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
3.34 USD
Average target price
5.401 USD
Spread / Average Target
+61.74%
Consensus

Quarterly revenue - Rate of surprise

  1. Stock
  2. Equities
  3. Stock HUTCHMED (China) Limited - London S.E.
  4. News HUTCHMED (China) Limited
  5. HUTCHMED (China) Initiates Bridging Study of Tazemetostat in Relapsed or Refractory Follicular Lymphoma Patients in China